Rankings
▼
Calendar
ACAD
ACADIA Pharmaceuticals Inc.
$4B
Q1 2022 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$115M
+8.4% YoY
Gross Profit
$113M
97.4% margin
Operating Income
-$113M
-97.9% margin
Net Income
-$113M
-97.9% margin
EPS (Diluted)
$-0.70
QoQ Revenue Growth
-11.7%
Cash Flow
Operating Cash Flow
-$76M
Free Cash Flow
-$76M
Stock-Based Comp.
$15M
Balance Sheet
Total Assets
$624M
Total Liabilities
$179M
Stockholders' Equity
$445M
Cash & Equivalents
$205M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$115M
$107M
+8.4%
Gross Profit
$113M
$102M
+10.5%
Operating Income
-$113M
-$67M
-69.3%
Net Income
-$113M
-$66M
-70.1%
← FY 2022
All Quarters
Q2 2022 →
ACAD Q1 2022 Earnings — ACADIA Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena